|NCT00000880 ||A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease||Completed||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 2||
The purpose of this study is to determine the safety and effectiveness of low doses of
cyclosporine (CsA) in patients with early HIV infection and to evaluate its effect on the
Activation of T cells (cells of the immune system) leads to HIV replication. Inhibition of
immune activation is therefore a potentially important area of therapy for patients with
early HIV infection. CsA is capable of decreasing T cell activation, which in turn may
decrease HIV replication.
|NCT00000936 ||A Study To Test An Anti-Rejection Therapy After Kidney Transplantation||Terminated||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 3||
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug
therapy, some patients will reject their new kidney. This study is designed to test two
anti-rejection approaches. Two medications in this study are currently used in children, but
there is no information regarding which drug is safer or more effective.
Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for
an improved post-transplant treatment, such as the induction therapy used in this study.
|NCT00048152 ||A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients||Completed||Hoffmann-La Roche||Phase 3||
This study will compare kidney function in kidney transplant patients following treatment
with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).
The anticipated time on study treatment is 6-12 months, and the target sample size is 500+
|NCT00064701 ||Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients||Completed||Astellas Pharma Inc||Phase 3||
The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate
mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney
|NCT00097968 ||Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy||Completed||Novartis Pharmaceuticals||Phase 3||
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection
that can happen after heart transplantation.
It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
The purpose of this study is to evaluate the change in kidney function after beginning
everolimus, while determining the most effective Neoral® (cyclosporine) dose to take with
everolimus, in adult cardiac transplant patients who have had their transplanted heart for
at least 1 year and who have cardiac allograft vasculopathy.
|NCT00098007 ||A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients||Completed||Novartis Pharmaceuticals||Phase 3||
The study is designed to evaluate whether Neoral dose optimization together with a
therapeutic drug monitoring of Certican will prevent renal dysfunction as observed in the
pivotal cardiac trial while maintaining the efficacy.
This objective will be assessed by comparing renal function post-transplant between 2 groups
|NCT00101738 ||Freedom Study: Myfortic in Kidney Transplant Patients||Completed||Novartis Pharmaceuticals||Phase 3||
The primary objective of the study is to evaluate that 3 immunosuppressant regimens will
have comparable kidney function results in kidney transplant patients.
|NCT00138970 ||Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk||Completed||University of Oslo School of Pharmacy||Phase 4||
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal
allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match,
receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid.,
aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun
Neoral® (full dose), CellCept® (1.0 g bid.) and prednisolone.
|NCT00148252 ||Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant||Terminated||University of Oslo School of Pharmacy||Phase 4||
To compare the change in renal function between CsA or MMF withdrawal from before to 12
months after drug withdrawal in renal transplant recipients on triple immunosuppressive
|NCT00150046 ||Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients||Completed||Novartis Pharmaceuticals||Phase 3||
This study will test the safety and efficacy of everolimus on heart transplant recipients.
This study is not recruiting in the United States.